1. National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant therapy;Pritchard;N Engl J Med,2006
2. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals;Anderson;Clin Cancer Res,2000
3. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors;Zaks;Cancer Res,1998
4. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide p369-377, results in short-lived peptide-specific immunity;Knutson;Clin Cancer Res,2002
5. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer;Murray;Clin Cancer Res,2002